ASTRAZENECA PRICES A $6 BILLION BOND ISSUE

RNS Number : 2715F

AstraZeneca PLC

11 November 2015

 



AstraZeneca prices a $6 billion bond issue

AstraZeneca PLC announces that yesterday it conducted a global bond market transaction by issuing a total of $6bn of notes. The proceeds of the issue will be used to fund the previously announced acquisition of ZS Pharma, Inc., to repay certain outstanding commercial paper obligations, and for general corporate purposes. The transaction, which is a global offering registered with the US Securities and Exchange Commission (SEC), consists of five tranches:

·     $0.4bn of 3-year floating rate notes;

·     $1.0bn of 3-year fixed rate notes with a coupon of 1.750%;

·     $1.6bn of 5-year fixed rate notes with a coupon of 2.375%;

·     $2.0bn of 10-year fixed rate notes with a coupon of 3.375%; and

·     $1.0bn of 30-year fixed rate notes with a coupon of 4.375%.

The notes will be issued under AstraZeneca's existing automatic shelf registration statement on Form F-3, which AstraZeneca filed with the SEC on 26 November 2013. Such registration statement provides for the offer and sale from time to time of an indeterminate amount of AstraZeneca's debt securities and includes a prospectus that investors should read to obtain more complete information. The offering was made solely by means of a written prospectus forming part of the effective registration statement.

A copy of the prospectus supplement and accompanying prospectus relating to the offering can be obtained by contacting Barclays Capital Inc. at [phone], HSBC Securities (USA) Inc at [phone], Merrill Lynch, Pierce, Fenner & Smith Incorporated at [phone] or Morgan Stanley & Co. LLC at [phone]. You may also get these documents for free by visiting EDGAR on the SEC website at www.sec.gov.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

The bond issuance does not have any material impact to the Company's financial guidance for 2015.

11 November 2015

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information about AstraZeneca please visit: www.astrazeneca.com.

CONTACTS

Media Enquiries
Esra Erkal-Paler		UK/Global	[phone]
Vanessa Rhodes		UK/Global	[phone]
Ayesha Bharmal		UK/Global	[phone]
Karen Birmingham		UK/Global	[phone]
Jacob Lund		Sweden	[phone]
Michele Meixell		US	[phone]
Investor Enquiries
UK
Thomas Kudsk Larsen	Oncology	[phone]	[phone]
Eugenia Litz	RIA	[phone]	[phone]
Nick Stone	CVMD	[phone]	[phone]
Craig Marks	Finance	[phone]	[phone]
Christer Gruvris	Consensus Forecasts	[phone]	[phone]
US
Lindsey Trickett	Oncology, ING	[phone]	[phone]
Mitch Chan	Oncology	[phone]	[phone]
Dial / Toll-Free		[phone]	[phone]

Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease,

ING - Infection, Neuroscience and Gastrointestinal

 

END

 

 

IODKMMMMMGVGKZZ